middle.news
EMVision Advances Portable Brain Scanner Trials with 57% Revenue Growth and Reduced Loss
9:13am on Monday 24th of August, 2026 AEST
•
Healthcare
Read Story
EMVision Advances Portable Brain Scanner Trials with 57% Revenue Growth and Reduced Loss
9:13am on Monday 24th of August, 2026 AEST
Key Points
Pivotal emu™ trial surpasses enrolment milestones across US and Australia
First Responder program shows strong aeromedical feasibility with key partners
Revenue rises 57% to $8.85 million driven by grants and R&D tax incentives
Net loss narrows 15% to $8.3 million amid expanded clinical and manufacturing activities
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Emvision Medical Devices (ASX:EMV)
OPEN ARTICLE